Moreover, p-EGFR in lung cancer cells has been identified as a potent CSC biomarker, associated with a strong sensitivity to anti-EGFR agents (e.g., erlotinib) in vitro and in vivo.47 The gene discussed is EGFR; the disease is lung carcinoma.